Neuropsychiatry

Here are some updates from the world of psychiatry throughout the month of February.

Neuropsychiatric disorders regularly occur following traumatic brain injury and are often diagnosed within the first year postinjury. Diagnosis and treatment of neuropsychiatric disorders can be difficult due to a number of interacting factors, such as preinjury psychiatric history, lesion location, injury severity, substance misuse, and psychosocial complications. Clinicians should use a highly individualized approach to diagnosis and treatment planning.

Psychiatric Times highlighted takeaways from the 2023 American College of Neuropsychopharmacology Annual Meeting in our February issue. Don't miss out on these important conference clinical pearls!

Available evidence from preclinical studies indicates that semaglutide shows promise for treating Alzheimer disease and Parkinson disease.

One meta-analysis that included data from 6 placebo-controlled and 7 active-controlled studies using subcutaneous semaglutide found that when compared with placebo, subcutaneous semaglutide 0.5 mg and 1 mg reduced hemoglobin A1c (HbA1c) by 1.01% and 1.38%, respectively.

From pain and suicidality in patients with depression to digital mental health interventions for adolescents with eating disorders, here are highlights from the week in Psychiatric Times.

A new study correlates reduced serotonin transporter and increased amyloid-ß deposition with cognitive deficits in mild cognitive impairment, suggesting a role for serotonergics in early Alzheimer disease.

From the impact of BMI on clinical features of bipolar disorder to FDA approval of the first integrated TMS system for MDD and OCD, here are highlights from the week in Psychiatric Times.

What is new in research on depression?

Biogen has officially announced its decision to discontinue all development and sales of aducanumab (Aduhelm) for Alzheimer disease.

Here are some updates from the world of psychiatry throughout the month of January.

The FDA granted clearance for a transcranial magnetic stimulation technology indicated for major depressive disorder and obsessive-compulsive disorder.

The experts weighed in on a wide variety of psychiatric issues for the January 2024 issue of Psychiatric Times.

From noninvasive brain stimulation for substance use disorders to updates from APSARD 2024, here are highlights from the week in Psychiatric Times.

Brain injury associated fatigue and altered cognition has been associated with a subset of individuals with mild traumatic brain injuries who develop posttraumatic hypopituitarism, including altered gut microbiome and amino acid utilization.

What is new in research on COVID-19 and mental health?

From a groundbreaking new launch for PTSD in the United States to connections between antidepressant treatment and metabolic syndrome, here are highlights from the week in Psychiatric Times.

The device is now available at 2 US clinics, with training and installation currently underway at several other locations.

Reviewing a year of CMEs in Psychiatric Times®

In this CME, learn more about the pathophysiology of HIV-associated neurocognitive disorder and to review the research and various tools used to aid in the diagnosis.

What neuromodulation can be used to specifically target nicotine users with schizophrenia? This research may tell us.

Check out these brief summaries on cognitive impairment in schizophrenia from an excellent session at the ACNP 2023 Annual Meeting!

DBS in psychiatry: What challenges stand between this treatment and success? Alik Widge, MD, PhD, shares more at the ACNP 2023 Annual meeting.

Research demonstrates a seasonal trend associated with stroke onset. More strokes occur between November and February than any other time period. Due to the holidays and other events, these months can be stressful and disrupt usual routines. Overeating, excessive alcohol intake, physical inactivity, and sleep deprivation frequently accompany the holidays and can increase risk for stroke. Clinicians can educate and provide strategies to effectively navigate the holiday season and potentially reduce risk for stroke.

Did you catch the President's Plenary at the ACNP 2023 Annual Meeting?

TMS for the treatment of neuropsychiatric symptoms in patients with long COVID appeared to improve their cognitive function and symptoms of depression.

From neurological abnormalities in first-episode psychosis to psychiatric boarding in emergency departments, here are highlights from the week in Psychiatric Times.

To image or not to image? Researchers performed a systematic review and meta-analysis of neuroradiological abnormalities in first-episode psychosis.

New positive data for brexpiprazole, the first and only treatment approved to treat agitation associated with dementia due to Alzheimer disease.

From sleep and neuroendocrine function following TBI to new phase 3 results from a clinical trial evaluating a promising new schizophrenia treatment, here are highlights from the week in Psychiatric Times.